New hope for nigerian women with aggressive breast cancer: targeted drug combo under study
NCT ID NCT06348134
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing a combination of anti-HER2 drugs (trastuzumab emtansine, pertuzumab, and docetaxel) plus hormone therapy (tamoxifen or letrozole) given before and after surgery in 74 Nigerian women with HER2-positive breast cancer. The main goal is to see if the cancer disappears completely by the time of surgery. The study also tracks side effects to assess safety.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Trastuzumab emtansine, pertuzumab, docetaxel, tamoxifen, letrozole
What this could lead to
If successful, this could show that a tailored anti-HER2 drug combination is safe and effective for Nigerian women, potentially improving breast cancer outcomes in this population.
What could go wrong
This is a small, early-phase trial (74 participants) with no control group, so results may not be conclusive. Side effects from chemotherapy and anti-HER2 drugs are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Lagos State University Teaching Hospital
RECRUITINGIkeja, Lagos, 100271, Nigeria
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
-
Lagos University Teaching Hospital
RECRUITINGYaba, Lagos, 100254, Nigeria
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
-
Obafemi Awolowo University Teaching Hospitals Complex (OAUTHC)
RECRUITINGIle-Ife, Osun State, 220005, Nigeria
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Ibadan Hospital
RECRUITINGIbadan, Oyo State, 200285, Nigeria
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••